The immunologicals group of the Binding Site, San Diego, has introduced two native tick-borne encephalitis (TBE) viral antigens to its broad offering of products for in vitrodiagnostic manufacturing and research applications. Both the standard and premium versions of the antigen are designed for use as a principle component within enzyme immunoassay testing procedures. The two antigens will benefit the needs of manufacturers of immunodiagnostic products, as well as clinical, biopharmaceutical, and life science researchers.
TBE is caused by the tick-borne encephalitis virus, a human pathogenic species among the flaviviruses. TBE manifests most often as meningitis, encephalitis, or meningoencephalitis. The disease typically follows an incubation period of 8 days after the initial bite and displays such nonspecific symptoms as headache, malaise, mild fever, nausea, and vomiting, after which the patient may develop neurological symptoms. The number of reported cases has been increasing in most countries, and TBE is posing a health challenge to Europe, as the number of reported human cases has increased by almost 400% over the past 3 decades.
Unique manufacturing techniques ensure the purity and lot-to-lot consistency of both antigens. Both feature a shelf-life stability of 10 years from the date of manufacture. The antigens come in a standard 1.0 mg vial. Larger bulk packaging configurations and test samples for evaluation are also available.
For more information visit the Binding Site.
